Compare SVV & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVV | TSHA |
|---|---|---|
| Founded | 1954 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | SVV | TSHA |
|---|---|---|
| Price | $9.28 | $3.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $14.23 | $13.00 |
| AVG Volume (30 Days) | 1.3M | ★ 3.5M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,678,954,000.00 | $9,773,000.00 |
| Revenue This Year | $6.18 | N/A |
| Revenue Next Year | $7.96 | $1,023.00 |
| P/E Ratio | $92.80 | ★ N/A |
| Revenue Growth | 9.19 | ★ 17.28 |
| 52 Week Low | $6.91 | $3.69 |
| 52 Week High | $13.88 | $7.30 |
| Indicator | SVV | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 19.82 |
| Support Level | $8.80 | N/A |
| Resistance Level | $9.59 | $6.68 |
| Average True Range (ATR) | 0.28 | 0.27 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 57.24 | 8.07 |
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.